Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like <b>Gottlieb</b> Lays Out Plans to Attract and Preserve Top Talent at the FDA July 17, 2017 SpineGuard Raises ???2 Million Of Fresh Equity Finance April 6, 2017 Safety Concerns Raised as Ionis Pharma's Inotersen Meets Both Primary Endpoints in Late-Stage Study May 14, 2017
Safety Concerns Raised as Ionis Pharma's Inotersen Meets Both Primary Endpoints in Late-Stage Study May 14, 2017